therapy? Now that Fc receptor crystal structures have been solved, will small molecule inhibitors of IgG ligand binding be useful? Can we block receptor signaling, as this family of activating receptors prefers lipid microdomains (rafts) in which to initiate signals via members of the src and syk protein tyrosine kinase families? Will additional ways be discovered to alter the balance of activating and inhibitory receptors to allow platelets to survive in circulation? The next step in the biology and therapy of ITP is more precise understanding of the origins of the disease and the promise of molecularly targeted therapy.
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